Current Report Filing (8-k)
November 15 2021 - 05:31PM
Edgar (US Regulatory)
0001053369 false 0001053369 2021-08-16
2021-08-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO
SECTION 13 OR 15(D)
OF THE
SECURITIES EXCHANGE ACT OF 1934
August 16, 2021
Date of
Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name
of registrant as specified in its charter)
|
Nevada |
|
001-15697 |
|
22-3542636 |
|
(State or
other jurisdiction |
|
(Commission |
|
(IRS
Employer |
|
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
165 Ludlow Avenue,
Northvale,
New Jersey
07647
(Address of
principal executive offices)
(201)
750-2646
(Registrant’s telephone
number, including area code)
(Former name
or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| |
|
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
ELTP |
|
OTCQB |
Item
2.02. Results of Operations and Financial Condition.
On August
16, 2021, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”)
filed its quarterly report on Form 10-Q for the quarter ended June
30, 2021, and, thereafter, issued a press release announcing its
financial results for that quarter. A copy of the press release is
furnished as Exhibit 99.1 hereto and is incorporated herein by
reference.
As noted in
the press release, the Company will host a conference call at 11:30
AM Eastern Daylight Time (EDT) on Tuesday, August 17, 2021, to
provide a general business update. Elite will respond to various
stockholder questions submitted prior to the call.
Conference Call
Information
|
Date: |
August 17,
2021 |
| Time: |
11:30 AM EDT |
| Dial- in
numbers: |
1-800-346-7359
(domestic) |
| |
1-973-528-0008
(international) |
| Conference number:
|
98840 |
| Questions: |
dianne@elitepharma.com |
| |
Financial questions by
7:00 PM EDT on Monday, August 16, 2021 |
| Audio Replay:
|
https://elite.irpass.com/events_presentations |
Item 7.01
Regulation FD Disclosure.
The
information disclosed in Item 2.02 above is incorporated into this
Item 7.01. The information included in this Current Report on Form
8-K (including the exhibit hereto) is being furnished under Item
2.02, “Results of Operations and Financial Condition,” Item 7.01,
“Regulation FD Disclosure” and Item 9.01 “Financial Statements and
Exhibits” of Form 8-K. As such, the information (including the
exhibit) herein shall not be deemed to be “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of
that Section, nor shall it be incorporated by reference into a
filing under the Securities Act of 1933, as amended, or the
Exchange Act, regardless of any general incorporation language in
such filing, except as shall be expressly set forth by specific
reference in such a filing. This Current Report (including the
exhibit hereto) will not be deemed an admission as to the
materiality of any information required to be disclosed solely to
satisfy the requirements of Regulation FD.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Dated:
August 16, 2021 |
ELITE
PHARMACEUTICALS, INC. |
|
|
By: |
/s/
Nasrat Hakim |
| |
|
Nasrat Hakim, President
and CEO |
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2022 to May 2022
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From May 2021 to May 2022
